ClinicalTrials.gg
TerminatedNCT00761514VIVIRUpdated Nov 19, 2009Results posted

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira

A Phase 4 interventional study of Humira (adalimumab) in Rheumatoid Arthritis, sponsored by Abbott. Terminated at 10 sites in Puerto Rico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-19.

Sponsored by Abbott · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was terminated due to low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
82nd of 87
14 · median 160
Started
2006
with 4 others
Phase 4
33 of 87
1 open now
Registered
29th of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 82nd largest by enrollment, is one of 5 that started in 2006, is one of 33 in phase 4, and was the 29th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate quality of life changes in Puerto Rican subjects with Rheumatoid Arthritis treated with Humira (adalimumab) as their first Anti-TNF Monoclonal Antibody.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has voluntarily signed and dated an form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific procedures.
  • Subject is 18 years of age or older.
  • If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of :

    • condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD).
    • contraceptives (oral or parenteral) for three months prior to study drug administration).
    • a vasectomized partner.
    • total abstinence from sexual intercourse.
  • If female, the results of a serum pregnancy test performed at Screening, prior to the first dose of Humira (adalimumab) must be negative.
  • Subject has confirmed diagnosis of active rheumatoid arthritis as defined by >= 6 swollen joints and >= 9 tender joints.
  • Subject has an Erythrocyte Sedimentation Rate (ESR) of > 20 mm/hr. ESR will be measured using the Westergren method.
  • Subject meets the American College of Rheumatology (ACR) criteria for diagnosis of rheumatoid arthritis (RA) for at least 3 months prior to enrollment and requires to be started in a biologic containing treatment for the first time, and the investigator chooses Humira (adalimumab).
  • Subject has had unsatisfactory response or intolerance to one or more prior disease-modifying antirheumatic drugs (DMARDS) (e.g., hydroxychloroquine, leflunomide, methotrexate, parenteral gold, sulfasalazine, azathioprine or any combination of those).
  • Subject will have an evaluation for latent tuberculosis with a tuberculosis (TB) skin test done in the screening visit. Subjects who have evidence of prior TB infection should be given prophylaxis in accordance with Centers for Disease Control and Prevention (CDC) guidelines.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have had prior treatment with cyclophosphamide, chlorambucil or any other Tumor Necrosis Factor (TNF) biologic as etanercept, infliximab, anakinra, abatacept and adalimumab.
  • Subjects who have been previously treated with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in persistent CD4 lymphopenia (CD4 lymphocytes \<= 500/mm3).
  • Subject has had prior treatment with intravenous (IV) immunoglobulin or any agent within 30 days of screening visit.
  • Subject has a history of cancer within the past 10 years other than resected basal cell or squamous cell carcinomas of the skin.
  • Subject has a history of malignant lymphoma or leukemia regardless of time since diagnosis.
  • Subject has a history of or current acute inflammatory joint disease of origin other than RA, e.g., Mixed Connective Tissue Disease (MCTD), Systematic Lupus Erythematosus (SLE), etc.
  • Subject has a history of uncontrolled diabetes mellitis, unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent cerebrovascular accident (CVA) (within 3 months) which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  • Subject has a history of active tuberculosis or listeriosis, or other active infections suggestive of significant or profound , such as Pneumocystis carinii, aspergillosis or other systemic protozoan or fungal infections.
  • Subject has a positive serology for or indicating active infection.
  • Subject has a history of positive status defined by an enzyme-linked immunosorbent assay (ELISA) positive test confirmed by a Western blot test and/or polymerase chain reaction (PCR).
  • Subject has had a persistent or severe infection(s) requiring hospitalization or treatment with intravenous (IV) antibiotics within 30 days, or oral antibiotics within 14 days, prior to enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    1

    All subjects will receive Adalimumab

    Drug: Humira (adalimumab)

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 24 in Average Score on Section 1 of the Modified Multi-Dimensional Health Assessment Questionnaire (mHAQ) That Includes Ratings of Sleep, Anxiety, Depression or Feeling Blue, and Ability to do Daily Activities.

    Section 1 of the mHAQ includes subject ratings of difficulty in: dressing; getting out of bed; lifting a full glass to the mouth; walking outdoors on flat ground; bathing; bending to pick up clothes from floor; getting in/out of car, bus, train, plane; walking 2 miles; participating in sports and games; getting a good night's sleep; dealing with feelings of anxiety, being nervous; dealing with feelings of depression, feeling blue. Without any difficulty=0, With some difficulty=1, With much difficulty=2, Unable to do=3. Ratings are summed. The maximum total score is 39. Low total score is good.

    Time frame: Week 24 of treatment

Secondary outcomes

  1. Percent Change From Baseline to Week 24 in Average Score on the Short Disease Activity Score

    On visual analog scale (VAS), patient marks activity of rheumatoid arthritis in previous 24 hours (0 mm=no symptoms; 100 mm=very active). On another VAS, patient marks how much pain (0 mm=no pain; 100 mm=severe pain) he/she had because of the illness in previous week. Patient also marks tender joints and swollen joints on body diagrams. Number of swollen and painful joints and values on VAS are used with erythrocyte sedimentation rate to calculate the patient's global assessment of disease activity. High score indicates high activity.

    Time frame: Week 24 of treatment

07

Results

Posted Nov 19, 2009
Limitations and caveats
This study was terminated early due to lack of enrollment. Only 7 subjects completed 24 weeks of treatment. That number is too small to provide reliable data on the effectiveness of the treatment.

Participant flow

Subjects were enrolled at 10 study sites in Puerto Rico beginning in November 2006.

Participant flow — Overall Study
MilestoneOpen-label Treatment With 40 mg Adalimumab Every Other Week
Started14
Completed7
Not completed7
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1
Withdrew: Health insurance didn't cover study drug1
Withdrew: Problem complying with study visit1
Withdrew: Unable to pay for medications1

Outcome measures

SecondaryPercent Change From Baseline to Week 24 in Average Score on the Short Disease Activity Score

On visual analog scale (VAS), patient marks activity of rheumatoid arthritis in previous 24 hours (0 mm=no symptoms; 100 mm=very active). On another VAS, patient marks how much pain (0 mm=no pain; 100 mm=severe pain) he/she had because of the illness in previous week. Patient also marks tender joints and swollen joints on body diagrams. Number of swollen and painful joints and values on VAS are used with erythrocyte sedimentation rate to calculate the patient's global assessment of disease activity. High score indicates high activity.

Time frame:
Week 24 of treatment
Reported as:
Number · Percent change in average score
Percent Change From Baseline to Week 24 in Average Score on the Short Disease Activity Score
Percent change in average scoreOpen-label Treatment With Adalimumab 40 mg Every Other Week
Percent Change From Baseline to Week 24 in Average Score on the Short Disease Activity Score31
PrimaryPercent Change From Baseline to Week 24 in Average Score on Section 1 of the Modified Multi-Dimensional Health Assessment Questionnaire (mHAQ) That Includes Ratings of Sleep, Anxiety, Depression or Feeling Blue, and Ability to do Daily Activities.

Section 1 of the mHAQ includes subject ratings of difficulty in: dressing; getting out of bed; lifting a full glass to the mouth; walking outdoors on flat ground; bathing; bending to pick up clothes from floor; getting in/out of car, bus, train, plane; walking 2 miles; participating in sports and games; getting a good night's sleep; dealing with feelings of anxiety, being nervous; dealing with feelings of depression, feeling blue. Without any difficulty=0, With some difficulty=1, With much difficulty=2, Unable to do=3. Ratings are summed. The maximum total score is 39. Low total score is good.

Time frame:
Week 24 of treatment
Reported as:
Number · Percent change in average total score
Percent Change From Baseline to Week 24 in Average Score on Section 1 of the Modified Multi-Dimensional Health Assessment Questionnaire (mHAQ) That Includes Ratings of Sleep, Anxiety, Depression or Feeling Blue, and Ability to do Daily Activities.
Percent change in average total scoreOpen-label Treatment With Adalimumab 40 mg Every Other Week
Percent Change From Baseline to Week 24 in Average Score on Section 1 of the Modified Multi-Dimensional Health Assessment Questionnaire (mHAQ) That Includes Ratings of Sleep, Anxiety, Depression or Feeling Blue, and Ability to do Daily Activities.59

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Treatment With 40 mg Adalimumab Every Other Week—2/14 (14.3%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
EventOpen-label Treatment With 40 mg Adalimumab Every Other Week
Oropharyngeal herpes simplex pharyngitisInfections and infestations1/14
Hospitalization due to fallInjury, poisoning and procedural complications1/14
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOpen-label Treatment With 40 mg Adalimumab Every Other Week
Erythema surrounding area of Humira injectionSkin and subcutaneous tissue disorders1/14
Erythema versicular rashSkin and subcutaneous tissue disorders1/14
Erythema rashSkin and subcutaneous tissue disorders1/14
FeverInfections and infestations1/14
Cellulitis right thighSkin and subcutaneous tissue disorders1/14
Sore throatInfections and infestations1/14
Epigastric painGastrointestinal disorders1/14
Non-pruritic areas of erythema on armsSkin and subcutaneous tissue disorders1/14
Nasal congestionGeneral disorders1/14
Dry mouthGeneral disorders1/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Open-label Treatment With 40 mg Adalimumab Every Other Week
<=18 years0
Between 18 and 65 years10
>=65 years4
Age Continuous
Age Continuous(years)Open-label Treatment With 40 mg Adalimumab Every Other Week
Mean61.29 ± 12.14
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Treatment With 40 mg Adalimumab Every Other Week
Female10
Male4
Region of Enrollment
Region of Enrollment(participants)Open-label Treatment With 40 mg Adalimumab Every Other Week
Puerto Rico14
08

Study locations

10 sites
  • Aguada, 00602, Puerto Rico
  • Bayamón, 00961, Puerto Rico
  • AJP Med, Inc. PSA
    Caguas, 00726, Puerto Rico
  • Caguas, 00726, Puerto Rico
  • Humacao, 00777, Puerto Rico
  • Manati, 00674, Puerto Rico
  • Rio Piedras, 00923, Puerto Rico
  • Rio Piedras, 00927, Puerto Rico
  • San Juan Arthritis & Research Center
    San Juan, 00910, Puerto Rico
  • San Juan, 00918, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2008
First posted
Sep 29, 2008
Start
Nov 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Nov 19, 2009
Last update
Nov 19, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00761514
Lead sponsor
Abbott
First posted
Sep 29, 2008
Start date
Nov 2006
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Nov 19, 2009
Last update
Nov 19, 2009

Study contacts

Carlos R. Rivera-Vàzquez, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion